论文部分内容阅读
目的探讨经皮动脉导管药盒系统(PCS)栓塞化疗原发性肝癌的临床疗效及不良反应。方法将84例原发性肝癌患者随机分为治疗组和对照组。治疗组45例肝癌患者经皮股动脉穿刺插管植入PCS后,常规每月1次经PCS栓塞化疗,同时经PCS每天注入顺铂(DDP)30mg～40mg,连续3天;注入5氟脲嘧啶(5Fu)0.5g～0.75g,连续5天;注入羟基喜树碱(HCPT)10mg,连续10天;10天为1疗程,每4周重复1次,共3～4个疗程。对照组39例肝癌患者常规每月1次经皮股动脉穿刺插管栓塞化疗,每月1次灌注HCPT30mg～40mg、DDP80mg～100mg、5Fu1.0g～1.5g,并行栓塞化疗,每4周重复1次,共3～4疗程。结果治疗组45例患者CR1例,PR30例,NC11例,PD3例,近期有效(CR+PR)率68.89%;对照组39例患者CR0例,PR18例,NC15例,PD6例,近期有效(CR+PR)率46.15%;两组比较有显著性差异(P<0.05)。两组毒副反应主要为胃肠道反应和骨髓抑制,两组比较无差异(P>0.05)。结论经PCS栓塞化疗(介入治疗)原发性肝癌近期疗效高,毒副反应小,且手术操作简便、安全有效,是治疗肝癌的一条有效途径。
Objective To investigate the clinical efficacy and adverse reactions of percutaneous arterial catheterization (PCS) embolization in the treatment of primary liver cancer. Methods 84 patients with primary liver cancer were randomly divided into treatment group and control group. Forty-five patients with hepatocellular carcinoma after percutaneous femoral artery puncture were treated with PCS chemosurgery once a month for 45 patients with hepatocellular carcinoma in the treatment group. Cisplatin (DDP) 30mg ~ 40mg was injected daily into the PCS for 3 consecutive days. Pyrimidine (5Fu) 0.5g ~ 0.75g for 5 consecutive days; injection of hydroxy camptothecin (HCPT) 10mg for 10 days; 10 days for a course of treatment, repeated once every 4 weeks, a total of 3 to 4 courses. Control group of 39 cases of patients with hepatocellular carcinoma routine percutaneous femoral artery puncture and catheter embolization chemotherapy once per month perfusion HCPT30mg ~ 40mg, DDP80mg ~ 100mg, 5Fu1.0g ~ 1.5g, concurrent embolization chemotherapy, repeated every 4 weeks Times, a total of 3 to 4 courses. Results Among the 45 patients in the treatment group, there were CR1, PR30, NC11 and PD3, and the rate of CR + PR was 68.89%. CR0, PR18, NC15 and PD in the control group were significantly higher than those in the control group + PR) rate was 46.15%. There was significant difference between the two groups (P <0.05). The two groups of side effects mainly gastrointestinal reactions and bone marrow suppression, no difference between the two groups (P> 0.05). Conclusion The treatment of primary hepatic carcinoma by PCS embolization chemotherapy (PCI) has high curative effect, less toxic and side effects, simple and safe operation, and is an effective way to treat liver cancer.